Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 in uncontrolled allergic asthma (52-week randomized trial)
2014-003155-57Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and severe asthma comparing QGE031 arm with Placebo arm (2 arms). Primary endpoint: Number of exacerbations within 52 weeks in atopic patients. Started Apr 2015; status: completed.
02
Drugs
ligelizumab
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on 2014-003155-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003155-57.